Research in prostate cancer could speed up drastically with a new breakthrough in prostate cancer cells grown in-vitro which could transform future drug trials.
Lawson Health Research Institute, Memorial Sloan Kettering Cancer Center, the Royal Marsden and Epic Sciences conducted an international mutual study which discovered a novel blood test that can foresee advanced prostate cancer patient response to particular treatments, resulting in better survival.
Along with new drug partner Merck, the British drugmaker displayed results showing that adding Lynparza to Johnson & Johnson prostate cancer fighter Zytiga was a more potent disease-fighter than Zytiga alone. As compared to a time-frame of 8.2 months for solo Zytiga, the combo effectively prevented disease progression for 13.8 months.
Pfizer $PFE and J&J $JNJ have come down to the wire with pivotal data on nonmetastatic prostate cancer. And there are billions of dollars in revenue on the line here.
The number of men dying from prostate cancer has overtaken the number of women dying from breast cancer for the first time, with the disease now the UK’s third biggest cancer killer.
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.